Skip to Main Content

Paper Details

No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized Trial.
Open Forum Infect Dis
15
2019
3TC, ASPIRE, DTG, Dolutegravir, HIV, HIV-1 RNA, Lamivudine, dolutegravir, lamivudine
Author NameAffiliation
Paul E SaxBrigham and Women's Hospital, Harvard Medical School
Vincent C MarconiEmory University School of Medicine and Rollins School of Public Health
Carl J FichtenbaumUniversity of Cincinnati
  • 1 - 3

Datasets

Release 1.2